Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lysine vasopressin (also known as lypressin or Lysipressin) is a cyclic nonapeptide hormone that functions as an antidiuretic. It is the porcine form of the antidiuretic hormone, differing from arginine vasopressin by having a lysine at position 8 instead of an arginine. Lysine vasopressin acts primarily on the kidneys to promote water reabsorption and reduce urine output, thereby concentrating urine and conserving body water. It also increases blood pressure by inducing moderate vasoconstriction through its action on specific G-protein-coupled receptors in vascular smooth muscle. Clinically, it has been used to treat diabetes insipidus and to improve blood pressure in cases of hypotension or shock[1][2][4][5]. Its use in humans has largely been replaced by desmopressin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lysine vasopressin.